Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials

Author:

Kim Jae Hyun1,Ta Casey N1,Liu Cong1,Sung Cynthia2,Butler Alex M1,Stewart Latoya A1,Ena Lyudmila1,Rogers James R1ORCID,Lee Junghwan1,Ostropolets Anna1,Ryan Patrick B134,Liu Hao1,Lee Shing M5,Elkind Mitchell S V67,Weng Chunhua1

Affiliation:

1. Department of Biomedical Informatics, Columbia University, New York, New York, USA

2. Health Services and Systems Research, Duke-NUS Medical School, Singapore

3. Observational Health Data Sciences and Informatics, New York, New York, USA

4. Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA

5. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA

6. Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA

7. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA

Abstract

Abstract Objective This research aims to evaluate the impact of eligibility criteria on recruitment and observable clinical outcomes of COVID-19 clinical trials using electronic health record (EHR) data. Materials and Methods On June 18, 2020, we identified frequently used eligibility criteria from all the interventional COVID-19 trials in ClinicalTrials.gov (n = 288), including age, pregnancy, oxygen saturation, alanine/aspartate aminotransferase, platelets, and estimated glomerular filtration rate. We applied the frequently used criteria to the EHR data of COVID-19 patients in Columbia University Irving Medical Center (CUIMC) (March 2020–June 2020) and evaluated their impact on patient accrual and the occurrence of a composite endpoint of mechanical ventilation, tracheostomy, and in-hospital death. Results There were 3251 patients diagnosed with COVID-19 from the CUIMC EHR included in the analysis. The median follow-up period was 10 days (interquartile range 4–28 days). The composite events occurred in 18.1% (n = 587) of the COVID-19 cohort during the follow-up. In a hypothetical trial with common eligibility criteria, 33.6% (690/2051) were eligible among patients with evaluable data and 22.2% (153/690) had the composite event. Discussion By adjusting the thresholds of common eligibility criteria based on the characteristics of COVID-19 patients, we could observe more composite events from fewer patients. Conclusions This research demonstrated the potential of using the EHR data of COVID-19 patients to inform the selection of eligibility criteria and their thresholds, supporting data-driven optimization of participant selection towards improved statistical power of COVID-19 trials.

Funder

National Library of Medicine

National Center for Advancing Clinical and Translational Science

Publisher

Oxford University Press (OUP)

Subject

Health Informatics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3